Format

Send to

Choose Destination
Nat Rev Immunol. 2019 Jun;19(6):369-382. doi: 10.1038/s41577-019-0127-6.

Macrophages as regulators of tumour immunity and immunotherapy.

Author information

1
Department of Medicine, ICCE Institute, Department of Pathology and Immunology, Siteman Cancer Center, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA. ddenardo@wustl.edu.
2
Department of Immunology, Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. brian.ruffell@moffitt.org.

Abstract

Macrophages are critical mediators of tissue homeostasis, with tumours distorting this proclivity to stimulate proliferation, angiogenesis and metastasis. This had led to an interest in targeting macrophages in cancer, and preclinical studies have demonstrated efficacy across therapeutic modalities and tumour types. Much of the observed efficacy can be traced to the suppressive capacity of macrophages, driven by microenvironmental cues such as hypoxia and fibrosis. As a result, tumour macrophages display an ability to suppress T cell recruitment and function as well as to regulate other aspects of tumour immunity. With the increasing impact of cancer immunotherapy, macrophage targeting is now being evaluated in this context. Here, we discuss the results of clinical trials and the future of combinatorial immunotherapy.

PMID:
30718830
DOI:
10.1038/s41577-019-0127-6

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center